It is possible, that the patients with BRAF mutant melanoma, treated with targeted therapy had worse outcomes because there was no access to PD-1 inhibitors or combination immunotherapy after progression, however, pembrolizumab was available within nine months of dabrafenib and trametinib access. This evidence concerns the gene BRAF and melanoma.